<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921906</url>
  </required_header>
  <id_info>
    <org_study_id>R&amp;D no 1701366</org_study_id>
    <nct_id>NCT02921906</nct_id>
  </id_info>
  <brief_title>Effect of Food Composition on Postprandial Insulin Secretion in Neonatal Diabetes</brief_title>
  <acronym>FoND</acronym>
  <official_title>Assessing the Effect of Food Composition on Postprandial Insulin Secretion in KCNJ11 Neonatal Diabetes (FoND Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Devon and Exeter NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Devon and Exeter NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neonatal diabetes is diagnosed before 6 months of age and causes high blood glucose levels&#xD;
      due to the pancreas not secreting insulin. Neonatal diabetes can be caused by a change in a&#xD;
      DNA region called the KCNJ11 gene. KCNJ11 encodes a channel in the pancreas that acts as a&#xD;
      switch to turn 'on' and 'off' insulin secretion. A change in KCNJ11 results in a faulty&#xD;
      channel, which keeps insulin secretion 'switched off'. The diabetes can be treated with&#xD;
      tablets called sulphonylureas that switch the pancreatic channel 'on', allowing it to secrete&#xD;
      insulin in response to gut hormones called incretins. Previous research has shown that&#xD;
      patients who switch from insulin to sulphonylureas have better blood glucose control,&#xD;
      including fewer episodes of hypoglycaemia (glucose dropping too low), and also avoid the need&#xD;
      for injections. It is thought that serious side effects from sulphonylureas are uncommon in&#xD;
      KCNJ11 neonatal diabetes. Some patients report low glucose after meals and we think this may&#xD;
      be because they make too much insulin if they eat a meal with protein but low amounts of&#xD;
      carbohydrate. The investigators will test this by giving study participants different meals&#xD;
      and measuring the amount of insulin, glucose and incretin hormone in the blood afterwards.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anecdotal evidence from routine clinical care suggests that patients with&#xD;
      sulphonylurea-treated KCNJ11 neonatal diabetes, when they eat, may experience mild&#xD;
      hypoglycaemia if the food consumed lacks carbohydrate. It has been suggested that this may be&#xD;
      due to regulation of insulin secretion via the incretin pathway as opposed to the classical&#xD;
      ATP pathway. Therefore the investigators hypothesise that foods with a relatively high&#xD;
      protein content compared to those with a relatively high carbohydrate content will result in&#xD;
      excessive insulin secretion and relatively lower glucose values in KCNJ11 patients. This&#xD;
      would be in contrast to healthy control subjects or subjects with SU-treated T2D where the&#xD;
      insulin secretion will be moderated by the ambient glucose via the classical ATP pathway. The&#xD;
      investigators will formally study this hypothesis by comparing the insulin, glucose and&#xD;
      incretin hormone responses to a high protein meal with a high carbohydrate meal in people&#xD;
      with KCNJ11 neonatal diabetes, people without diabetes and people with sulphonylurea-treated&#xD;
      Type 2 Diabetes. To assess whether any effect seen is due to direct stimulation of the beta&#xD;
      cell by the sulphonylurea itself, people with KCNJ11 neonatal diabetes will also undergo the&#xD;
      same tests in the fasting state, having taken the sulphonylurea in the absence of any food.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose levels</measure>
    <time_frame>240 minutes</time_frame>
    <description>Glucose AUC after each meal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin levels</measure>
    <time_frame>240 minutes</time_frame>
    <description>Insulin AUC after each meal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GLP-1 levels</measure>
    <time_frame>240 minutes</time_frame>
    <description>GLP-1 AUC after each meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIP levels</measure>
    <time_frame>240 minutes</time_frame>
    <description>GIP AUC after each meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon levels</measure>
    <time_frame>240 minutes</time_frame>
    <description>Glucagon AUC after each meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paracetamol levels</measure>
    <time_frame>240 minutes</time_frame>
    <description>Rate of change of paracetamol levels after each meal as marker of gastric emptying.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neonatal Diabetes</condition>
  <arm_group>
    <arm_group_label>Neonatal diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>People with neonatal diabetes due to mutations in the KCNJ11 gene who are treated with sulphonylureas and not on insulin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-diabetic controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>People without diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls with Type 2 Diabetes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>People with Type 2 diabetes who are treated with sulphonylurea medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High protein meal</intervention_name>
    <description>Breakfast with high protein / low carbohydrate content</description>
    <arm_group_label>Controls with Type 2 Diabetes</arm_group_label>
    <arm_group_label>Neonatal diabetes</arm_group_label>
    <arm_group_label>Non-diabetic controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High carbohydrate meal</intervention_name>
    <description>Breakfast with high carbohydrate / low protein content</description>
    <arm_group_label>Controls with Type 2 Diabetes</arm_group_label>
    <arm_group_label>Neonatal diabetes</arm_group_label>
    <arm_group_label>Non-diabetic controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.</description>
    <arm_group_label>Controls with Type 2 Diabetes</arm_group_label>
    <arm_group_label>Neonatal diabetes</arm_group_label>
    <arm_group_label>Non-diabetic controls</arm_group_label>
    <other_name>Acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fasting state - sulphonylurea only</intervention_name>
    <description>People with diabetes take sulphonylurea medication in the absence of any food stimulus</description>
    <arm_group_label>Neonatal diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥8yrs.&#xD;
&#xD;
          -  Willing and able to provide informed consent (adults i.e. participants aged &gt;16&#xD;
             years).&#xD;
&#xD;
          -  Willing and able to provide assent and parents willing to provide informed consent&#xD;
             (children and young people &lt;16 years).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;8yrs.&#xD;
&#xD;
          -  Unable/unwilling to provide informed consent (adults).&#xD;
&#xD;
          -  Unable/unwilling to provide assent (children) or parents unwilling to provide informed&#xD;
             consent.&#xD;
&#xD;
          -  Known liver disease or chronic renal impairment (EGFR &lt;60ml/min).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew T Hattersley, BMBCh DM FRS</last_name>
    <role>Study Chair</role>
    <affiliation>University of Exeter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pamela Bowman, MBBS MA</last_name>
    <phone>01392408325</phone>
    <email>P.Bowman@exeter.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bea A Knight, PhD</last_name>
    <phone>01392408172</phone>
    <email>B.A.Knight@exeter.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Exeter Clinical Research Facility</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX25DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Bowman, MBBS MA</last_name>
      <phone>01392408325</phone>
      <email>P.Bowman@exeter.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Bea A Knight, PhD</last_name>
      <phone>01392408172</phone>
      <email>B.A.Knight@exeter.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 20, 2016</study_first_submitted>
  <study_first_submitted_qc>September 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2016</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin</keyword>
  <keyword>Glucose</keyword>
  <keyword>Incretin</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Food</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infant, Newborn, Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

